Withdrawal Phenomena

The following offers a simple clinical system for evaluating the intensity of the abstinence syndrome  

Goosefiesh Dilated pupils Anorexia Muscle tremor 

For assaying the intensity of abstinence on a day-to-day or hour-to-hour basis, Himmelsbach and Andrews (54) assigned the numerical values given in Table 2. The intensity of the abstinence syndrome is given by the sum of the points scored. 

POINT SYSTEM POB MEASURING ABSTINENCE SYNDROME INTENSITY BY THE DAY OR BY THE HOUR (HIMMELSBACH AND ANDREWS, 54) 

Fever (for each 0.1° C. rise over mean addic- 1 1 10 

---

Administration of sufficient doses of an opioid antagonist after only a single therapeutic dose of morphine results in withdrawal phenomena (Bickel et al. 1987 Heishman et al. 1989 Jones 1979). Some degree of physical dependence... 

Tolerance and dependence occur with both BZD and non-BZD compounds abrupt discontinuation results in withdrawal phenomena such as anxiety, agitation, restlessness, and hypertension. Tolerance, especially to the hypnotic effect, is known to occur, so an increase in dose is required to obtain the same effect (Liappas et al. 2003). 

Physical withdrawal phenomena drug preference tests... 

The question remains, are the nicotine withdrawal phenomena in the rodent models sufficiently aversive to exert a motivational effect This can be tested by whether rodents will avoid an enviromnent associated with precipitated nicotine abstinence syndrome, in comparison with an enviromnent associated only with a saline injection. Significant place aversion conditioned to nicotine withdrawal has been repeatedly observed in rodent models (Balfour 2002 Goktalay et al. 2006 Malin et al. 2006 Suzuki et al. 1996 Watkins et al. 2000). 

Cancer l/6th as potent as morphine Side effects quantitatively similar to those of morphine some withdrawal phenomena 200... 

Type E (end-of-use) reactions occur with rebound withdrawal phenomena. 

The occurrence of withdrawal phenomena are possibly the clearest indication of dependence in the... 

Evidence also supports a clinically significant rebound-withdrawal phenomena between doses of alprazolam, sometimes referred to as interdose or breakthrough symptoms (233, 234). Mellor and Jain (218) raised the possibility that some long-term diazepam users may be subject to a similar phenomenon ... 

Other than slow taper, no consistently effective treatment to alleviate withdrawal symptoms has been reported. Although several compounds have been studied (e.g., b-blockers, clonidine, carbamazepine, abercamil, ondansetron), results have been contradictory ( 250). Carbamazepine, however, may be useful in seizure-prone patients (251). Valproate (VPA) has also been reported to benefit patients undergoing BZD discontinuation after long-term dependence ( 252), which may be related to VPA s potential anxiolytic properties, its ability to alleviate withdrawal phenomena, or both. The azaspirone anxiolytic buspirone has been reported ineffective in suppressing withdrawal symptoms, particularly in long-term BZD users (253, 254). Hydroxyzine has also been found beneficial in treating patients for lorazepam withdrawal (255). 

Kales A, Bixler EO, Vela-Bueno A, et al. Alprazolam effects on sleep and withdrawal phenomena. J Clin Pharmacoi 1987 27 508-515. 

Gradual tapering of a BZD before delivery to minimize any neonatal withdrawal phenomena... 

Schopf, J. (1983) Withdrawal phenomena after long-term administration of benzodiazepines. A review of recent investigations , Pharmacopsychiatry, 16 1-8. 

The ultra short-acting hypnotic, zaleplon was assessed in insomniac outpatients [48], The doses of zaleplon were 5, 10, and 20 mg and compared to placebo over 4 weeks. Pharmacological tolerance did not develop during treatment with zaleplon, nor were rebound insomnia and withdrawal phenomena apparent. 

S.C. Dilasaver, Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Safety 10 103-114, 1994. 

Reboimd and withdrawal phenomena occur erratically. In general, they are more likely with drugs having a short half-life (abrupt drop in plasma concentration) and pure agonist or antagonist action. They are less likely to occur with drugs... 

Nattel S, Rangno RE, Van Loon G. Mechanism of propranolol withdrawal phenomena. Circulation 1979 59(6) 1158-64. 

Rangno RE, Langlois S, Lutterodt A. Metoprolol withdrawal phenomena mechanism and prevention. Clin Pharmacol Ther 1982 31(1) 8-15. 

Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. Br J Clin Pharmacol 1982 13(Suppl 2) S345-51. 

Kajdasz DK, Moore JW, Donepudi H, Cochrane CE, Malcolm RJ. Cardiac and mood-related changes during short-term abstinence from crack cocaine the identification of possible withdrawal phenomena. Am J Drug Alcohol Abuse 1999 25(4) 629-37. 

BuSpar (buspirone) An antianxiety drug that is not often associated with abuse because of the absence of withdrawal phenomena, cognitive impairment, and sedation. It has a short half-life and therefore must be taken several times daily. It is also said not to have the same addicting or euphoric quality that is often noted in the benzodiazepines. BuSpar is not a benzodiazepine and is referred to as a nonbenzodiazepine. BuSpar is generally prescribed for a limited time to help control the symptoms of anxiety and allows the client to be calmer while learning new ways of coping with anxiety-producing events. 

The dosage can be increased, over and above the physical requirements to maintain physical comfort and avoid withdrawal phenomena, in an effort to recapture the original sensation of pleasure. For many addicts, this dosage is sufficiently large to be beyond their financial grasp. The addict then usually submits to treatment and on release, soon relapses into the comfort of his drug. 

---